Iwama et al. 2025

Quick Summary

This 2025 paper by Iwama and colleagues adds an important group of people to the growing IRF2BPL story. The researchers studied 10 individuals from nine families who had developmental delay, epilepsy, movement symptoms, or a mixture of these features. Genetic testing found nine pathogenic IRF2BPL variants. Eight of these variants were newly reported in this paper, so the study meaningfully expands the list of IRF2BPL changes that clinicians and laboratories may need to recognize.

Earlier IRF2BPL papers often emphasized truncating variants, which are gene changes that shorten the protein. This cohort is different because many patients carried missense variants, where one amino acid in the protein is changed, or an in-frame deletion-insertion that changes a small stretch of the protein without shifting the whole code. The paper therefore helps show that IRF2BPL syndrome is not limited to one kind of genetic change.

Clinically, the study shows a broad pattern rather than one single course. Several children had early-onset seizures, including West syndrome, epileptic spasms, tonic seizures, or migrating focal seizures. Many had developmental delay, absent or delayed speech, autism spectrum features, or low developmental testing scores. Some had movement findings such as dystonia, axial hypotonia, ataxia, hypertonia, or abnormal gait. MRI and EEG findings also varied: some scans were normal, while others showed cortical atrophy, cerebral atrophy, widened sulci, periventricular leukoencephalopathy, or other changes.

For families, the main message is that IRF2BPL syndrome can look different from person to person. A child with a missense variant may have severe early epilepsy and developmental delay. Another person with a truncating variant may have later dystonia and movement decline. The paper supports careful long-term follow-up and careful interpretation of each person's exact variant and clinical course.

Why This Paper Matters

This article matters because it broadens both sides of the IRF2BPL picture: the genetics and the lived clinical presentation. It does not simply say that IRF2BPL variants cause disease. It shows that different kinds of variants, in different regions of the gene, can be associated with different neurological patterns.

The public article abstract reports that exome sequencing in 10 patients from nine families found nine pathogenic IRF2BPL variants, including five missense variants, one in-frame indel, and three truncating variants. That balance is important. If clinicians only think about stop-gain or frameshift changes, they may miss families whose variant changes one amino acid or changes a small part of the protein while leaving the rest intact.

The paper is also useful because it connects patient descriptions with a broader genetic map. The researchers compared reported pathogenic variants with benign variants and highlighted regions of IRF2BPL where disease-causing and harmless variation appear differently distributed. For non-specialist readers, the practical meaning is that location matters. A variant's effect is not only about whether the gene name is IRF2BPL, but also about what kind of change it is and where it lands in the protein.

The article also reinforces a biological clue about IRF2BPL. The abstract describes IRF2BPL as a single-exon gene encoding a transcription factor with zinc-finger domains that may help regulate WNT signaling in the nervous system. WNT signaling is one of the systems cells use during development. This does not yet translate into a treatment, but it gives researchers a pathway to investigate when asking why IRF2BPL changes affect brain development, seizures, and movement.

What The Researchers Studied

This was a primary cohort study. The researchers did not only review previously published families. They reported 10 individuals from nine families and paired genetic findings with detailed clinical information. The public article preview provides the headline findings, while the supplementary clinical document gives patient-by-patient descriptions and the supplementary spreadsheet summarizes variants and selected clinical fields.

The study used exome sequencing to identify IRF2BPL variants in people with neurological symptoms. The patients were not all the same age and did not all have the same first symptom. Some were infants or young children with epilepsy and developmental delay. Others were older individuals with dystonia, gait problems, hypotonia, or developmental history. This matters because it keeps the paper from reducing IRF2BPL syndrome to only one age window or one symptom.

The confirmed cohort contains 10 patient rows because one family included twins, listed as Patient 4a and Patient 4b, who shared the same in-frame deletion-insertion variant. The nine families therefore produced nine distinct variants across 10 affected individuals. The source table and patient narratives were both needed for extraction: the spreadsheet gave structured variant and clinical summary fields, while the supplementary narrative gave richer details about seizures, development, MRI, EEG, and movement symptoms.

What Was Learned About Symptoms

The paper shows that seizures were common, but not universal. Patient 1 had non-convulsive epileptic status at 2 years 7 months and later myoclonic and tonic-clonic seizures. Patient 2 had epileptic spasms, West syndrome, and later focal seizures that were difficult to control. Patient 3 had infantile spasms with hypsarrhythmia and later tonic or hypermotor seizures. The twin sisters, Patients 4a and 4b, had West syndrome. Patient 5 had epilepsy of infancy with migrating focal seizures. Patient 6 had body twitching and epileptic spasms. Patient 7 had complex febrile seizure clusters. In contrast, the spreadsheet coded Patients 8 and 9 as having no seizures, although Patient 8's narrative described sudden motionless episodes without labeling them as seizures.

Developmental findings were also frequent, but varied in severity. Patient 1 is an important exception: the source table described development as normal, and the narrative said she spoke two-word sentences and ran by age 2. Other patients had clear delays. Patient 2 had delayed eye pursuit and head control, could roll over but could not sit alone, and had no meaningful words. Patient 3 had profound developmental delay, delayed motor milestones, no spoken words at 10 years, and autistic features. The twins had global developmental delay and autism spectrum diagnoses. Patient 7 had psychomotor delay, no walking, and no speaking by age 4. Patient 9 had mild global developmental delay since childhood.

Movement symptoms were a major part of the cohort. Dystonia was reported in the structured table for the in-frame indel twins, Patient 5, Patient 6, Patient 8, and Patient 9. Patient 8 developed worsening dystonia from around age 16 and later axial hypotonia, reduced movement, and dysphagia. Patient 9 had dystonia in the upper and lower limbs, athetotic hand movements, axial hypotonia, wide-based gait, hypertonia, wheelchair use, and limited upward eye movements. Patient 6 was the only source-table row coded with ataxia, but several narratives included gait or balance-related movement concerns.

EEG findings helped document epilepsy in several children. Patient 2 had multifocal spikes and abnormal background activity. Patient 3 had hypsarrhythmia and later modified hypsarrhythmia. Patient 5 had ictal EEG findings that migrated between brain regions and interictal spikes. Patient 6 had periodic generalized spike-and-wave activity. Patient 7's EEG was reported as non-significant at 2 years 1 month.

MRI findings were mixed. Patient 1 had right-hemisphere cortical atrophy after earlier brain swelling. Patient 2 had frontal subarachnoid space dilatation, and the figure legend later noted mild cerebellar hypoplasia. Patient 3 had an initially normal MRI but later mild widening of frontal and temporal sulci. The twins had periventricular leukoencephalopathy in the neonatal period and later cerebral atrophy. Patients 5, 6, 7, and 8 had normal or non-significant brain MRI findings in the narrative. Patient 9's spreadsheet MRI field was not determined.

What Was Learned About Genetics

The cohort included nine pathogenic variants in IRF2BPL. Five were missense variants: `c.748C>G` / `p.Leu250Val`, `c.1160C>T` / `p.Pro387Leu`, `c.1402T>C` / `p.Ser468Pro`, `c.1487C>T` / `p.Pro496Leu`, and `c.1490A>C` / `p.Gln497Pro`. A missense variant changes one amino acid in the protein. These changes do not shorten the protein, but this paper supports that they can still be clinically important.

One variant was an in-frame deletion-insertion: `c.1484_1486delinsCGT` / `p.Leu495_Pro496delinsProSer`. This was found in the twin sisters. The supplementary figure notes that two de novo variants were in cis, meaning they were on the same copy of the gene, and should be described together as this combined delins variant.

Three variants were truncating frameshift variants: `c.276_313del` / `p.Ala93Thrfs*27`, `c.501del` / `p.Gln167Hisfs*12`, and `c.546del` / `p.Ser182Argfs*30`. Frameshift variants disrupt the reading frame and usually create a shortened protein. In this cohort, the truncating rows were not all identical clinically: Patient 7 had developmental delay and febrile seizure clusters, while Patients 8 and 9 had prominent dystonia and movement issues and were coded as not having seizures in the structured source table.

The paper's larger genetic message is that IRF2BPL variant interpretation should not stop at broad categories. Missense, in-frame, and truncating changes can all matter, but their clinical patterns may differ. The article supports looking at the variant type, the exact protein position, the patient history, and published patient-level comparisons together.

Patient And Cohort Details

Patient 1 was an 8-year-old girl with `p.Leu250Val`. She had normal early motor and language development but later developed seizures, including non-convulsive epileptic status and myoclonic and tonic-clonic seizures. MRI showed right-sided cortical atrophy. She also had ADHD.

Patient 2 was a 4-year-old boy with `p.Pro387Leu`. He had West syndrome, focal seizures, developmental delay, no meaningful words, abnormal EEG, and MRI changes involving the frontal subarachnoid space, with later mild cerebellar hypoplasia noted in the figure legend.

Patient 3 was a 10-year-old girl with `p.Ser468Pro`. She had refractory epilepsy, profound developmental delay, autistic features, no spoken words at age 10, hypsarrhythmia, and later mild widening of sulci on MRI.

Patients 4a and 4b were twin girls with the same in-frame `p.Leu495_Pro496delinsProSer` variant. Both had West syndrome, global developmental delay, autism spectrum diagnoses, dystonia in the source table, and MRI evidence of cerebral atrophy after neonatal periventricular leukoencephalopathy.

Patient 5 was a 5-month-old girl with `p.Pro496Leu`. She had tonic seizure clusters beginning at 3 months, epilepsy of infancy with migrating focal seizures, abnormal EEG, delayed development, and a normal MRI.

Patient 6 was a 2-year-old boy with `p.Gln497Pro`. He had body twitching from 8 months, epileptic spasms, loss of eye pursuit, abnormal EEG, developmental delay on Bayley testing, hand stereotypies, body rocking, and normal brain MRI and PET.

Patient 7 was a 4-year-old girl with `p.Ala93Thrfs*27`. She had relative microcephaly, psychomotor delay, no walking or speaking, complex febrile seizure clusters, and non-significant MRI and EEG findings at 2 years 1 month.

Patient 8 was a 23-year-old man with `p.Gln167Hisfs*12`. The narrative described dystonia, early falls, worsening balance, pervasive developmental disorder diagnosis, axial hypotonia, progressive reduction in motility, dysphagia, and normal brain MRI. There is a source discrepancy because the spreadsheet sex field decodes as female, while the narrative clearly describes a man.

Patient 9 was a 37-year-old woman with `p.Ser182Argfs*30`. She had mild global developmental delay since childhood, later staggering gait, axial hypotonia, limb hypertonia, wheelchair use, generalized dystonic spasms, athetotic hand movements, wide-based gait, and limited upward eye movements.

What Families Can Take Away

This paper supports a broad, careful view of IRF2BPL syndrome. Some people may present in infancy with severe epilepsy and developmental delay. Others may have later movement symptoms, dystonia, hypotonia, or gait changes. Even within one paper, the range is wide enough that families should be cautious about assuming one person's course predicts another person's course.

The study also shows why genetic reports should be interpreted with patient details, not in isolation. A missense variant can be meaningful. A truncating variant can appear with different symptom patterns. A small in-frame change can be associated with epilepsy, autism features, developmental delay, and MRI findings. The exact variant, the person's symptoms, and the published evidence all need to be considered together by clinicians and genetic counselors.

For families already living with an IRF2BPL diagnosis, the paper does not provide a treatment. It does, however, add practical knowledge for recognition and follow-up: seizures, development, speech and communication, movement, swallowing, MRI, and EEG can all be relevant, but not every person will have every feature.

Limits Of The Paper

The cohort is still small: 10 people from nine families. That is valuable for a rare disorder, but it is not enough to predict every possible outcome for every IRF2BPL variant. The paper can show patterns and expand the known spectrum, but it cannot define a precise prognosis for a newly diagnosed child.

Some data fields are incomplete or inconsistent across sources. The spreadsheet summarizes selected clinical features, while the narrative gives richer detail. In a few places they differ, such as Patient 8's sex field, Patient 3's MRI summary, and the MRI status of Patients 6 and 7. Those differences are documented in the cohort audit and should be kept visible rather than silently smoothed over.

The paper also does not test a therapy. Treatments such as ACTH, valproic acid, ketogenic diet, carbamazepine, risperidone, etizolam, or levodopa appear in individual histories, but the study was not designed to compare treatments or prove what works best. Clinical decisions still belong with each person's medical team.

Source Notes

• Main article preview and abstract: article title, publication details, 10 patients from nine families, nine pathogenic variants, eight novel variants, variant type breakdown, and WNT-signaling context.
• Supplementary clinical DOCX: `Detailed clinical information`, Families 1-9.
• Supplementary figure legends: MRI findings for individuals 1-5, EEG findings for individuals 2 and 5, and cis interpretation of the twin variant.
• Supplementary XLSX: `This study` rows for Patients 1-9, including variant, sex, seizure, seizure onset, dystonia, ataxia, developmental delay, and MRI summary fields.
• Verified cohort files: `extracted-source-table.csv`, `patients.csv`, and `source-audit.md` in this article folder.